LCTX Share Price | Lineage Cell Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Lineage Cell Therapeutics, Inc.?

Market Cap: As of Jun 18, Lineage Cell Therapeutics, Inc. has a market capitalization of 196.02 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Lineage Cell Therapeutics reported net sales of 9.56 million and a net profit of -16.16 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 78.38 million and total assets of 113.22 million.

Q: What does Lineage Cell Therapeutics, Inc. do?

Overview: Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for age-related degenerative diseases and other serious medical conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 196.02 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.59 Return on Equity: -26.06% Price to Book: 2.48Contact Details: Address: 2173 Salk Ave Ste 200, CARLSBAD CA: 92008-7354 Tel: 1 510 5213390 Fax: 1 510 5213389 Website: http://www.biotimeinc.com/

Q: Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?

As of 12 August 2021, the valuation grade for Lineage Cell Therapeutics, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.95, EV to Sales of 11.24, and ROE of -26.06%. In comparison to peers, Lineage Cell Therapeutics has a significantly higher EV to EBITDA ratio of -5.19 compared to Poseida Therapeutics, Inc. at -13.3266 and Verastem, Inc. at -3.5165, suggesting it is less efficient in generating earnings relative to its enterprise value. Additionally, while the company has shown impressive stock returns year-to-date at 208.46%, outperforming the S&P 500's 12.22%, its long-term performance over 3 years and 5 years is lackluster compared to the benchmark, which raises concerns about its sustainability.

Q: Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Lineage Cell Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. However, the weekly RSI remains bearish, indicating some short-term weakness. The company has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 208.46% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish, with strong indicators driving this sentiment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

90.7 k

Shareholding (Sep 2025)

FII

1.82%

Held by 41 FIIs

DII

87.38%

Held by 24 DIIs

Promoter

0.01%

How big is Lineage Cell Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Lineage Cell Therapeutics, Inc. has a market capitalization of 196.02 million, with net sales of 9.56 million and a net profit of -16.16 million over the latest four quarters. The company reported shareholder's funds of 78.38 million and total assets of 113.22 million as of Dec 24.

View full answer

What does Lineage Cell Therapeutics, Inc. do?

22-Jun-2025

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for age-related degenerative diseases and serious medical conditions. As of March 2025, it has a market cap of $196.02 million, with net sales of $2 million and a net loss of $4 million.

View full answer

Who are in the management team of Lineage Cell Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Lineage Cell Therapeutics, Inc. includes Chairman Alfred Kingsley, CEO Brian Culley, and several independent directors: Deborah Andrews, Don Bailey, Neal Bradsher, Stephen Farrell, and Michael Mulroy. This team combines executive leadership with independent governance.

View full answer

Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

Lineage Cell Therapeutics, Inc. is currently considered risky and overvalued due to its negative P/E ratio, poor returns on capital, and high EV to Sales ratio, despite impressive year-to-date stock returns that raise concerns about long-term sustainability.

View full answer

Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Lineage Cell Therapeutics, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 208.46%.

View full answer

Compare Lineage Cell Therapeutics, Inc. with Similar Stocks

Verastem, Inc.Poseida Therapeutics, Inc.Akoya Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 382 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.79

Return on Equity

-80.84%

Price to Book

17.35

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Jun 2025)

Net Profit:

-30 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.69%

6 Months

75.11%

1 Year

136.62%

2 Years

61.54%

3 Years

18.31%

4 Years

15.07%

5 Years

-33.86%

Lineage Cell Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

52.80%

EBIT Growth (5y)

5.37%

EBIT to Interest (avg)

-28.88

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.17

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.12%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.95

EV to EBIT

-5.04

EV to EBITDA

-5.19

EV to Capital Employed

3.33

EV to Sales

11.24

PEG Ratio

Dividend Yield

ROCE (Latest)

-66.01%

ROE (Latest)

-26.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 21 Schemes (10.79%)

Foreign Institutions

Held by 41 Foreign Institutions (1.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 86.67% vs -48.28% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -641.46% vs -24.24% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.80",
          "val2": "1.50",
          "chgp": "86.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-6.30",
          "chgp": "23.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.60",
          "val2": "2.30",
          "chgp": "-1,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.40",
          "val2": "-4.10",
          "chgp": "-641.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,786.60%",
          "val2": "-4,330.90%",
          "chgp": "254.43%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.74% vs -39.46% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.49% vs 18.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.50",
          "val2": "8.90",
          "chgp": "6.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.90",
          "val2": "-24.00",
          "chgp": "12.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "-0.20",
          "chgp": "1,150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.60",
          "val2": "-21.50",
          "chgp": "13.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,261.10%",
          "val2": "-2,765.00%",
          "chgp": "50.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

2.80

1.50

86.67%

Operating Profit (PBDIT) excl Other Income

-4.80

-6.30

23.81%

Interest

0.00

Exceptional Items

-27.60

2.30

-1,300.00%

Consolidate Net Profit

-30.40

-4.10

-641.46%

Operating Profit Margin (Excl OI)

-1,786.60%

-4,330.90%

254.43%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 86.67% vs -48.28% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -641.46% vs -24.24% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

9.50

8.90

6.74%

Operating Profit (PBDIT) excl Other Income

-20.90

-24.00

12.92%

Interest

0.00

Exceptional Items

2.10

-0.20

1,150.00%

Consolidate Net Profit

-18.60

-21.50

13.49%

Operating Profit Margin (Excl OI)

-2,261.10%

-2,765.00%

50.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 6.74% vs -39.46% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 13.49% vs 18.56% in Dec 2023

All Annual Results

Company CV

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).

Company Coordinates

Company Details

2173 Salk Ave Ste 200 , CARLSBAD CA : 92008-7354

Tel: 1 510 5213390

http://www.biotimeinc.com/

Registrar Details

Lineage Cell Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Lineage Cell Therapeutics, Inc.?

Watch in Real-Time

What does Lineage Cell Therapeutics, Inc. do?

Who are in the management team of Lineage Cell Therapeutics, Inc.?

Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?

Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?

Compare Lineage Cell Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Lineage Cell Therapeutics, Inc.

Company Coordinates